SLC5A2 and Hypoglycemia: A recent meta-analysis has not shown an increased risk of hypoglycaemia with the administration of SGLT2 inhibitors alone, and this is in accordance with the mechanism of action of these drugs that are not able to increase the release of insulin or influence the glucose synthesis (11).